HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. - Wikidata - awgldk - TriplyDB

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

http://www.wikidata.org/entity/Q34612818

about

VIN usual type-from the past to the future Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations Capsomer vaccines protect mice from vaginal challenge with human papillomavirus Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10-16 years Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica.Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses Peptidic inhibitors for in vitro pentamer formation of human papillomavirus capsid protein l1.Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.Therapeutic cancer vaccines: current status and moving forward.Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.A review of clinical trials of human papillomavirus prophylactic vaccines.Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)Burden of cervical, anal, and oral HPV in an inner-city pre-vaccine adolescent population.Vaccine delivery using nanoparticles.Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention Rare subtype(s) and frequency of multi-viral subtype high-risk human papilloma virus infection in high-grade squamous intraepithelial lesion and squamous cell carcinoma in a cervical carcinoma prevalent developing country: a multiplex real-time poly Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.

P2860

Q26865303-6080BD25-ADA8-4A8F-9910-2A6E7C92087B Q28611356-9EEF3B32-E924-4FBB-898A-6EAFBC2B2A3D Q28729883-A8218F1F-46CF-4CED-8657-4B931B6424D0 Q28743261-150FCA06-C385-4B22-B4FF-B69BCC449013 Q30300329-EF48848A-0FA3-43B9-9B5B-74DAA867005F Q30353668-4CCF16FB-F4C6-4D87-B96E-E7496F7DD571 Q30406365-37C6BD32-DAD0-4A2A-9260-C259E217BFEB Q30970916-199951E2-DE9C-475D-9E4A-A1D0362AE51A Q31159398-6EDD6741-1152-4B7A-8F43-C95BA5888245 Q33572691-03161FD7-E3BF-4DA6-B551-8CD848877E75 Q33723312-04139E0E-028E-4184-9EEF-E51D8D367782 Q34152234-A8DF7B70-A695-4FBF-9958-6F2F54C3F7F1 Q34199773-1A740BCC-AE9E-4518-9374-4EC9D0984AB5 Q34236633-84722640-A5E5-4398-A586-AD85C7D39792 Q34395881-116991C2-B9D4-4610-A389-0A74AD35F7C1 Q34492140-14BBB928-B012-4A36-BC87-5B6048414FFF Q34571825-8C0121B6-B015-4BD8-A6CC-6B55305541D4 Q34708325-E663431B-25B3-448A-9E6C-0AC1CF7B0B0A Q34802732-F5F0F139-385B-4014-97B9-CEEF0F8EB6AE Q34994905-607F0539-1422-45C9-A8C7-C6A9A661BBC8 Q35379036-147607A3-AC48-4161-9DAE-AD516FF16885 Q35805297-90BC99AF-F797-4A9C-8B86-5042D3EB7682 Q35818648-B762780A-7C93-46CC-87D6-C69E0C456F41 Q35861286-E5FB72AE-2EEF-44BB-8119-6B1982BAB15F Q35886468-11326CB8-DDCD-44EB-8E07-E8EDC4880068 Q35887709-C1238591-A4E4-46DD-BE6E-CF55D5CD3508 Q35894347-366C18E8-24A2-4120-9D25-1D92CF7C9E65 Q35918838-B39AF9D2-1121-40AA-A86C-148496A00B29 Q35985515-7D457890-E2CC-4BCC-B920-A7E539998E73 Q36259403-4DE858FA-6291-4315-A51C-3B3E2FAB79AC Q36480943-062E8F86-DFFF-4D09-811D-B1CD9A7BFC9D Q36629357-AFD2741B-4806-4254-A726-2BDF2D77D1BD Q36712817-FD54C234-4CCA-4E93-8030-4C10553BD078 Q36736614-EC74BE89-0434-45A4-8476-D4209E326260 Q37162220-0A69DB70-0FE9-45B5-A575-752C753C8097 Q37274559-3EB8D871-D98D-4FB1-9EF4-11A1461C1E77 Q37278764-0B5994E3-92FA-4BB2-AEAC-FDBA20F6CB9B Q37384735-AF0F464C-FC9C-4601-9569-AA8974D7955E Q37466826-9CC83ED5-955C-48F4-A461-C5E12444F295 Q37526148-48EC59E5-79A4-4E18-B376-1AEE1145A675

P2860

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

http://www.wikidata.org/entity/Q34612818

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@ast

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@en

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@nl

type

label

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@ast

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@en

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@nl

prefLabel

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@ast

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@en

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@nl

P1433

Q34612818-D4C19BFB-48A2-424C-8734-C1BE081BE2B3

P1476

Q34612818-535CAFF2-CFE0-44AA-94E7-0D73BC0182D1

P2093

Q34612818-047466EE-BD44-4D8A-AFDA-58E2038E2E8E

Q34612818-0B47A111-F2BC-4323-B874-EE964061B107

Q34612818-0BB9E413-C358-4B98-8EB9-B585EDA1A17B

Q34612818-52D3B3B9-8EAD-4F86-B883-1FBC8FB3EB73

Q34612818-7209B768-A216-4398-AA80-80A604E4BB05

Q34612818-962DC00C-EB07-478C-AFF8-A0E078C76AF6

Q34612818-A54FA25F-A4BC-4DEF-84CE-D1631FB33A1C

Q34612818-C336318F-5F87-4128-B870-5E9D4B005FF5

P2860

Q34612818-18AC5EF4-6AEB-47DC-B165-6ED37CF9C36A

Q34612818-37ECCBD2-54A0-40E9-810F-4C9F358B82DB

Q34612818-6A7F4B60-F706-4D60-89AC-5E275C68B2A5

Q34612818-6F91BD11-B47F-4DEA-83CA-0F20938B7C84

Q34612818-7293ECF9-1299-4572-869A-4240F1C91F9F

Q34612818-880C4D2D-CDE7-4BCA-897F-4230D4D21798

Q34612818-9C12F38F-A03B-4254-9E8B-9BDC4E905C1C

Q34612818-9E226219-774B-4CE9-93EF-D45DFA6CE3A6

Q34612818-B7B4BF3E-B90C-4259-8689-2C06B32162B3

Q34612818-BE1270E7-6BA1-4B2C-AECF-CE8478A4C5E2

P304

Q34612818-16A33CF3-37A1-4668-A69B-FD294EF1B7B6

P31

Q34612818-7D4622B8-9C41-49E3-B1CB-01BFE33E4297

P356

Q34612818-B3D99A71-63DB-4CB9-A6F2-B2232B4BE33C

P407

Q34612818-5931C8C8-6F88-47E0-9E9C-CE816CC69FAB

P433

Q34612818-8B962FDF-6360-4089-A143-E3648114E15D

P478

Q34612818-4DDA1679-76C2-4989-A85A-8631EDED3596

P50

Q34612818-3B3B542F-12F1-47CA-A2A5-5781D70B65E8

Q34612818-422C5D0D-FCA1-4AD7-807B-55062C006B4B

P577

Q34612818-5769E2CE-80E1-4DA7-A116-208C7CC72763

P5875

Q34612818-445721DA-3F69-4FB6-BD22-418266B483D9

P698

Q34612818-E0B6660D-21B7-469E-8AEF-50BDB3501817

P921

Q34612818-42B42856-B022-42A6-911B-D326B45D7C95

P932

Q34612818-684E64E6-F350-4B14-9439-0CAEE3F92BB9

P356

J.VACCINE.2011.01.001

P1433

P1476

HPV16/18 L1 VLP vaccine induce ...... may mediate cross-protection.

@en

P2093

Carolina Porras

http://www.w3.org/2001/XMLSchema#string

Douglas R Lowy

http://www.w3.org/2001/XMLSchema#string

John T Schiller

http://www.w3.org/2001/XMLSchema#string

Joseph G Dauner

http://www.w3.org/2001/XMLSchema#string

Ligia A Pinto

http://www.w3.org/2001/XMLSchema#string

Rolando Herrero

http://www.w3.org/2001/XMLSchema#string

Troy J Kemp

http://www.w3.org/2001/XMLSchema#string

Yuanji Pan

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

P304

2011-2014

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2011.01.001

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Allan Hildesheim

Mahboobeh Safaeian

P577

2011-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49761915

http://www.w3.org/2001/XMLSchema#string

P698

21241731

http://www.w3.org/2001/XMLSchema#string

P921

P932

3046309

http://www.w3.org/2001/XMLSchema#string